Hi, I'm doctor Michael Bishop. I am director of the David and Etta Jonas Center for Cellular Therapy at the University of Chicago. And I'm at, 2024 annual meeting of the American Society of Hematology here in San Diego.

Yeah, I have the privilege, on behalf of my co-investigators to talk about anito-cel, which is a very unique, anti-BCMA CAR T-cell therapy, and that has a unique receptor, which is different than other anti-BCMA CARs. It's a synthetic receptor. Instead of being derived from the monoclonal antibody.

And I am presenting the long term results, with antio-cell. What is very unique is that we were very surprised that it has 100% response rate. And of those hundred response, 92% are very good partial responses are better and nearly 80% are complete responders.

So this for right now, in a phase 1 study, is incredibly remarkable and looks possibly to be best in class relative this, now in terms of long term results.

For those patients who do respond, the median progression free survival is two and a half years. This also appears to be the best results ever reported in terms of progression free survival. So that's very, very exciting.

Then to make things even better, the incidence of cytokine release syndrome and neurologic toxicities are also seem to be very, very good. Now the incidence of cytokine release syndrome is 95%. However, only one case was grade three. No grade four CRS. In the neurologic, toxicities, the incidence is 20% and only one case of grade three. No grade four.

So it's a very well tolerated product with a high degree of efficacy. Multiple relapse. Multiple myeloma patients who again, had to have seen a proteasome inhibitor, had to see an anti-CD38 monoclonal antibody and had to see an immune modulating drug. A significant proportion of these patients had undergone prior autologous stem cell transplantation.

So these patients at three or more lines of prior therapy. We have not seen any incidence of Parkinsonian like syndrome in any of these patients so far. And in our current follow up among this patient population, nor long term neurologic toxicities.

The phase 1 portion of the trial is, closed. And now it's just an a long term follow up. But there is actually a ongoing phase 2, which is nearing completion, and this will be a registration trial. And hopefully this will, we'll have the results of that next year's.

In this patient population. It was very, very limited because a study was started about, 4 or 5 years ago before other BCMA therapies were available. However, in subgroup of populations, I'm looking at patients with high risk disease and extra medullary disease. We're actually seeing very good responses. And that's another thing to this. All of the investigators are very, very excited about.

When you're doing a phase 1 study, you don't expect these types of results and say, well, the first patient went into a complete grave. The second patient went into a complete remission. And so, they actually looked at two cell dosing. And actually the lower dose was had even a better toxicity profile and yet still same degree of efficacy. And that's what's being investigated in the current phase 2 trial, which we are participating on at the University of Chicago.